Last updated: August 4, 2026
Adderall 10 mg is an immediate-release mixed amphetamine salts tablet containing equal proportions of four amphetamine salts. Its commercial market is mature, genericized, and regulated as a Schedule II controlled substance. Financial performance depends more on supply availability, DEA quota allocation, manufacturing reliability, and generic competition than on patent protection.
The brand product has no meaningful current exclusivity barrier. Generic mixed amphetamine salts 10 mg tablets are widely approved, while public company disclosures generally do not report Adderall 10 mg revenue as a separate product line. Market value is therefore best analyzed through prescription volume, generic pricing, shortage conditions, and manufacturer participation rather than through brand-level sales forecasts.
What is Adderall 10 mg and how is it regulated?
Adderall 10 mg immediate-release tablets contain:
| Component |
Function |
| Dextroamphetamine saccharate |
Amphetamine active ingredient |
| Amphetamine aspartate monohydrate |
Amphetamine active ingredient |
| Dextroamphetamine sulfate |
Amphetamine active ingredient |
| Amphetamine sulfate |
Amphetamine active ingredient |
The product is approved for attention-deficit/hyperactivity disorder and narcolepsy. The original product is listed in the FDA Orange Book under NDA 011522. Amphetamine mixed salts are Schedule II controlled substances under the federal Controlled Substances Act, which restricts refills, requires controlled-substance prescribing procedures, and subjects manufacturers to annual production quotas.[1][2]
The 10 mg strength is part of the immediate-release tablet line, commonly available in 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, and 30 mg strengths. Extended-release mixed amphetamine salts products, including Adderall XR, are separate dosage forms with different formulation and patent histories.
When does Adderall 10 mg lose exclusivity?
Adderall 10 mg lost meaningful market exclusivity years ago. The relevant product is now exposed to generic substitution and does not rely on a current patent-protected franchise.
| Exclusivity factor |
Status |
| Original small-molecule exclusivity |
Expired |
| Current branded patent barrier |
No material barrier identified for immediate-release 10 mg tablets |
| FDA generic pathway |
ANDA approval under section 505(j) |
| Biosimilar pathway |
Not applicable |
| Controlled-substance restrictions |
Remain active |
| Current commercial protection |
Manufacturing capacity, supply reliability, contracting, and distribution |
The original composition and formulation protections for immediate-release mixed amphetamine salts are expired. The FDA Orange Book remains the primary source for current patent and exclusivity listings, but an approved ANDA does not require a new clinical efficacy program when it demonstrates pharmaceutical equivalence, bioequivalence, and quality compliance.[1][3]
Patent expiry does not remove regulatory constraints. Generic manufacturers still need DEA registration, quota allocation, compliant controlled-substance manufacturing, and state-level distribution permissions.
What is the Orange Book status of Adderall 10 mg?
The Orange Book identifies the reference listed drug under NDA 011522. The immediate-release tablet is distinct from Adderall XR, which has a separate NDA and formulation profile.
A practical Orange Book assessment is:
| Issue |
Adderall immediate-release 10 mg |
| Reference listed drug |
Adderall tablets |
| NDA |
011522 |
| Dosage form |
Immediate-release tablet |
| Active ingredient |
Mixed amphetamine salts |
| Current marketing model |
Primarily generic |
| Listed unexpired patent protection |
No material current barrier identified |
| Pediatric exclusivity |
Expired |
| Orphan exclusivity |
Not applicable |
| 180-day generic exclusivity |
No current blocking exclusivity expected |
Orange Book listings can change as FDA updates patent certifications, discontinued-product designations, and active marketing status. The business implication is stable: immediate-release 10 mg tablets are an established generic market rather than an exclusivity-protected branded product.
How many patents cover Adderall 10 mg?
No current patent estate materially protects the basic immediate-release 10 mg mixed amphetamine salts tablet.
The historic intellectual-property position covered the amphetamine salt composition and immediate-release tablet technology. Those protections no longer prevent ANDA competition. Later patents associated with extended-release delivery, capsule technology, or abuse-deterrent approaches do not automatically apply to the immediate-release 10 mg tablet.
Patent risk is therefore low for the core product and higher only where a manufacturer introduces a differentiated product, such as:
- Extended-release delivery.
- Abuse-deterrent delivery.
- New combination products.
- Digital adherence or monitoring systems.
- New therapeutic indications.
- Formulations with nonstandard release profiles.
A generic manufacturer seeking to market a conventional immediate-release 10 mg tablet would generally face regulatory and manufacturing hurdles rather than a credible blocking-patent problem.
What companies manufacture generic Adderall 10 mg?
Generic mixed amphetamine salts tablets have been marketed by multiple FDA-approved manufacturers. The competitive set has included Teva Pharmaceuticals, Sandoz, Amneal Pharmaceuticals, Rhodes Pharmaceuticals, Lannett Company, Elite Pharmaceuticals, and other ANDA holders or contract manufacturers, depending on strength, package configuration, and marketing status.[4][5]
The active supplier list changes because controlled-substance manufacturing is sensitive to quota, inspection findings, plant interruptions, product discontinuations, and commercial allocation. A company may hold an ANDA without actively supplying every strength or package size.
Teva has had a particularly important market position because it has supplied both generic amphetamine mixed salts and other ADHD medicines. Amneal, Sandoz, Rhodes, and smaller manufacturers add supply but do not necessarily provide equivalent volume across all channels.
Which companies are challenging Adderall 10 mg?
Generic competition is already established rather than pending. The relevant competitors are ANDA sponsors and authorized generic suppliers, not Paragraph IV challengers seeking first market entry.
What is the Paragraph IV status?
Paragraph IV litigation is generally most relevant before generic entry, when an ANDA applicant challenges an unexpired Orange Book patent. For the conventional immediate-release 10 mg tablet, the principal composition and formulation patents are expired. The market therefore does not depend on a pending Paragraph IV case for generic access.
Any later patent dispute would more likely involve:
- A branded reformulation.
- A new delivery technology.
- A manufacturing process.
- A combination product.
- A method-of-use claim.
The absence of a current core patent barrier reduces litigation risk for standard generic entry but does not eliminate possible commercial disputes over supply contracts, trademarks, manufacturing rights, or controlled-substance compliance.
What caused Adderall shortages and how did they affect the market?
The 2022-2024 Adderall shortage changed the market from a simple price-erosion story into a supply-constrained market.
The FDA attributed shortages in part to manufacturing delays and increased demand. The Drug Enforcement Administration also controls annual production quotas for amphetamine active pharmaceutical ingredients and finished dosage forms. Quota management can limit the ability of manufacturers to respond rapidly when prescriptions rise.[2][6]
Key supply drivers included:
| Driver |
Market effect |
| Higher ADHD diagnosis and treatment demand |
Increased prescription volume |
| Telehealth prescribing expansion |
Broader access in some markets |
| DEA production quotas |
Limits aggregate supply growth |
| API shortages |
Constrains finished-dose production |
| Manufacturing delays |
Creates regional and strength-specific gaps |
| Pharmacy inventory policies |
Amplifies local shortages |
| Multiple generic suppliers |
Reduces dependence on one manufacturer but does not eliminate shortages |
The shortage increased substitution between manufacturers, raised pharmacy workload, and shifted demand toward alternative strengths, extended-release products, methylphenidate products, and lisdexamfetamine when available. It also reduced the commercial value of nominal market share because a manufacturer unable to fill orders could lose prescriptions immediately.
What is the financial trajectory for Adderall 10 mg?
Adderall 10 mg has a mature generic financial profile:
- Long-term unit demand is supported by chronic ADHD treatment.
- Brand revenue has been eroded by generic substitution.
- Generic pricing is pressured by multiple suppliers.
- Shortages can temporarily improve manufacturer pricing and utilization.
- DEA quotas and plant constraints limit the ability to monetize demand growth.
- Product-level revenue is generally not disclosed by public companies.
The market has two distinct economic phases.
Pre-shortage economics
Before the shortage, immediate-release mixed amphetamine salts was a commoditized generic product. Retail prices were shaped by payer contracts, pharmacy benefit managers, wholesaler purchasing, Medicaid reimbursement, and generic competition. Manufacturers competed on reliable supply, cost, and channel access.
Brand Adderall retained recognition and prescriber familiarity, but its economic position was limited by generic substitution. Brand pricing could remain higher than generic pricing, but prescription volume was heavily exposed to substitution rules and payer controls.
Shortage-period economics
During shortages, supply reliability became more valuable than nominal list price. Manufacturers with available inventory could gain short-term prescription volume and improve capacity utilization. The effect was uneven because controlled-substance quota restrictions prevented all suppliers from expanding at the same rate.
Shortage-driven pricing gains are unlikely to create durable franchise value. Once supply normalizes, generic competition should again pressure net prices. The main lasting beneficiaries are manufacturers with efficient plants, dependable API access, strong DEA compliance, and distribution relationships.
What is the revenue exposure for manufacturers?
Public disclosures generally combine Adderall 10 mg with broader portfolios, such as generic products, CNS medicines, or controlled substances. Standalone revenue for the 10 mg strength is not usually reported.
| Company type |
Revenue exposure |
| Branded originator |
Limited and declining for immediate-release product |
| Large generic manufacturer |
Moderate portfolio contribution, rarely disclosed by strength |
| Specialty generic company |
Potentially higher concentration risk |
| Contract manufacturer |
Exposure depends on customer agreements |
| Wholesaler or pharmacy |
Transaction volume rather than product-specific margin |
The product is commercially important as a recurring-volume generic, but it is unlikely to be a major standalone earnings driver for diversified pharmaceutical companies. For smaller generic manufacturers, the product can have greater significance because a limited number of controlled-substance products may account for a meaningful share of revenue.
How strong is the patent estate for Adderall 10 mg?
The core patent estate is weak as a commercial defense because the relevant immediate-release protections have expired. The stronger barriers are operational.
| Barrier |
Relative strength |
| Core composition patent |
Low, expired |
| Immediate-release formulation patent |
Low, expired |
| Regulatory exclusivity |
None material |
| DEA quota access |
Medium to high |
| API sourcing |
Medium to high |
| Controlled-substance compliance |
Medium |
| Manufacturing scale |
Medium to high |
| Distribution access |
Medium |
| Brand recognition |
Medium but insufficient against substitution |
This is a classic mature generic market: intellectual property has limited defensive value, while manufacturing execution determines market share.
What licensing deals affect Adderall 10 mg?
The most relevant transaction was Teva's acquisition of Actavis Generics from Allergan, completed in 2016. The transaction expanded Teva's generic portfolio and manufacturing footprint, including products in the central nervous system category.[7]
Takeda's acquisition of Shire in 2019 transferred Shire's broader pharmaceutical portfolio, but the commercial relevance of immediate-release Adderall is limited by generic erosion and the absence of current exclusivity.[8]
There is no widely disclosed, current licensing structure that gives one company durable control over the immediate-release 10 mg market. Supply, manufacturing, and distribution agreements are more important than royalty-bearing patent licenses.
What generic entry risks exist for Adderall 10 mg?
Generic entry risk is already realized. The remaining commercial risks are:
- Further price erosion when additional suppliers return to market.
- Loss of share from unreliable fulfillment.
- FDA warning letters or manufacturing restrictions.
- DEA quota reductions or delayed quota allocations.
- Substitution toward extended-release or non-amphetamine therapies.
- Reimbursement pressure from government and commercial payers.
- Reputational and regulatory scrutiny involving controlled-substance prescribing.
For branded Adderall, the principal risk is continued generic substitution. For generic manufacturers, the principal risk is operational interruption rather than patent invalidation.
How does Adderall 10 mg compare with Adderall XR and Vyvanse?
| Product |
Active ingredient |
Release profile |
Market protection |
Main competitive position |
| Adderall 10 mg IR |
Mixed amphetamine salts |
Immediate release |
Expired core protection |
Low-cost, flexible dosing |
| Adderall XR |
Mixed amphetamine salts |
Extended release |
Historic formulation protection, now largely expired |
Once-daily delivery |
| Vyvanse |
Lisdexamfetamine |
Long acting prodrug |
Brand exclusivity expired in 2023 |
Long duration and prodrug design |
| Generic methylphenidate IR |
Methylphenidate |
Immediate release |
Generic |
Non-amphetamine alternative |
| Generic methylphenidate ER |
Methylphenidate |
Extended release |
Product-specific |
Long-acting alternative |
Adderall 10 mg competes primarily on cost, titration flexibility, and availability. Adderall XR and Vyvanse compete on duration and convenience. Supply shortages can temporarily distort these relationships by directing patients toward whichever product is available.
What is the outlook for Adderall 10 mg through 2027?
The base case is stable demand with low price growth and intermittent supply volatility.
| Period |
Expected market condition |
| 2024-2025 |
Continued shortage sensitivity and uneven manufacturer availability |
| 2025-2026 |
Gradual normalization if API and quota constraints ease |
| 2026-2027 |
Mature generic competition, ongoing price pressure, stable therapeutic demand |
The strongest commercial positions will likely belong to manufacturers that maintain reliable supply and obtain adequate DEA quota. A major price expansion is unlikely without a prolonged shortage or meaningful supplier exit. A major patent-driven revenue event is also unlikely for the conventional immediate-release 10 mg tablet.
Key Takeaways
- Adderall 10 mg is an immediate-release mixed amphetamine salts tablet regulated as a Schedule II controlled substance.
- The core patent and exclusivity position has expired.
- The FDA reference product is listed under NDA 011522.
- Generic competition is established; Paragraph IV litigation is not the central market issue.
- Teva, Sandoz, Amneal, Rhodes, Lannett, Elite, and other suppliers have participated in the generic market across different periods and configurations.
- Shortages have been driven by demand growth, manufacturing constraints, API availability, and DEA quota controls.
- Public companies generally do not disclose revenue for the 10 mg strength separately.
- Long-term financial performance depends on supply reliability, manufacturing economics, and payer access.
- Brand revenue remains exposed to generic substitution.
- Biosimilar risk is not relevant because Adderall is a small-molecule drug.
FAQs About Adderall 10 mg Market and Patent Risk
Is Adderall 10 mg still patent protected?
No material current patent protection is expected to block generic immediate-release mixed amphetamine salts 10 mg tablets. The relevant historic protections have expired.
Can a generic company launch Adderall 10 mg without a Paragraph IV challenge?
Yes. An ANDA applicant can rely on expired patents and pursue approval through the standard abbreviated pathway. A Paragraph IV certification is not required when no relevant unexpired patent blocks the product.
Is Adderall 10 mg a biologic or biosimilar product?
No. Adderall 10 mg is a small-molecule drug. It is subject to generic-drug regulation, not the FDA biosimilar pathway.
Why can Adderall 10 mg remain unavailable despite many generic manufacturers?
DEA production quotas, API limitations, plant interruptions, and uneven distribution can constrain aggregate supply even when several companies hold approvals.
Is Adderall 10 mg a financially attractive generic product?
It can provide recurring volume, but it is a low-exclusivity product with price pressure. Its attractiveness depends on manufacturing cost, quota access, supply reliability, reimbursement, and the supplier's ability to avoid stockouts.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Drug Enforcement Administration. (2024). Established aggregate production quotas for schedule I and II controlled substances. https://www.deadiversion.usdoj.gov
-
U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA). https://www.fda.gov/drugs/types-applications/abbreviated-new-drug-application-anda
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). FDA drug shortages: Amphetamine mixed salts tablets. https://www.accessdata.fda.gov/scripts/drugshortages/
-
U.S. Food and Drug Administration. (2023). FDA announces shortage of amphetamine mixed salts products. https://www.fda.gov/drugs/drug-safety-and-availability
-
Teva Pharmaceutical Industries Ltd. (2016). Teva completes acquisition of Allergan's generics business. https://ir.tevapharm.com
-
Takeda Pharmaceutical Company Limited. (2019). Takeda completes acquisition of Shire. https://www.takeda.com/newsroom/featured-topics/shire-acquisition/
